Concurrent transcriptional deregulation of AML1/RUNX1 and GATA factors by the AML1-TRPS1 chimeric gene in t(8;21)(q24;q22) acute myeloid leukemia

Blood

Volumn 109, Issue 9, 2007, Pages 4023-4027

  Asou, Norio ^a   Yanagida, Masatoshi ^b,d   Huang, Liqun ^b   Yamamoto, Masayuki ^e   Shigesada, Katsuya ^d   Mitsuya, Hiroaki ^a   Ito, Yoshiaki ^b,c   Osato, Motomi ^b,c  

^a KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

^b INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d KYOTO UNIVERSITY   (Japan)

^e UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; IDARUBICIN; TRANSCRIPTION FACTOR GATA 1; TRANSCRIPTION FACTOR RUNX1; ZINC FINGER PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; CASE REPORT; CELL PROLIFERATION; GENE TRANSLOCATION; HEMATOPOIETIC CELL; HUMAN; LEUKEMOGENESIS; MALE; PRIORITY JOURNAL; TRANSCRIPTION REGULATION;

EID: 34247347362     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-01-031781     Document Type: Article

References (25)

1. Ogawa E, Inuzuka M, Maruyama M, et al. Molecular cloning and characterization of PEBP2 beta, the heterodimeric partner of a novel Drosophila runt-related DNA binding protein PEBP2 alpha. Virology. 1993;194:314-331.
2. Asou N. The role of a Runt domain transcription factor AML1/RUNX1 in leukemogenesis and its clinical implications. Crit Rev Oncol Hematol. 2003;45:129-150.
3. Osato M. Point mutations in the RUNX1/AML1 gene: another actor in RUNX leukemia. Oncogene. 2004;23:4284-4296.
4. Speck NA, Gilliland DG. Core-binding factors in haematopoiesis and leukaemia. Nat Rev Cancer. 2002;2:502-513.
5. Miyoshi H, Shimizu K, Kozu T, Maseki N, Kaneko Y, Ohki M. t(8;21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, AML1. Proc Natl Acad Sci U S A. 1991;88:10431-10434.
6. Jeandidier E, Dastugue N, Mugneret F, et al. Abnormalities of the long arm of chromosome 21 in 107 patients with hematopoietic disorders: a collaborative retrospective study of the Group Francais de Cytogenetique Hematologique. Cancer Genet Cytogenet. 2006;166:1-11.
7. Huret JL, Senon S. Atlas of Genetics and Cytogenetics in Oncology and Haematology. http://www.infobiogen.fr/services/chromcancer/Genes/ AML1.html. Accessed June 20, 2006.
8. Miyawaki S, Sakamaki H, Ohtake S, et al. A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia. Cancer. 2005;104:2726-2734.
9. Osato M, Asou N, Okubo T, et al. Myelomonoblastic leukaemia cells carrying the PEBP2β/MYH11 fusion gene are CD34+, c-KIT + immature cells. Br J Haematol. 1997;97:656-658.
10. Osato M, Asou N, Abdalla E, et al. Biallelic and heterozygous point mutations in the runt domain of the AML1/PEBP2alphaB gene associated with myeloblastic leukemias. Blood. 1999;93:1817-1824.
11. Yamashita N, Osato M, Huang L, et al. Haploinsufficiency of Runx1/AML1 promotes myeloid features and leukaemogenesis in BXH2 mice. Br J Haematol. 2005;131:495-507.
12. Kagoshima H, Akamatsu Y, Ito Y, Shigesada K. Functional dissection of the alpha and beta subunits of transcription factor PEBP2 and the redox susceptibility of its DNA binding activity. J Biol Chem. 1996;271:33074-33082.
13. Malik TH, Shoichet SA, Latham P, Kroll TG, Peters LL, Shivdasani RA. Transcriptional repression and developmental functions of the atypical vertebrate GATA protein TRPS1. EMBO J. 2001;20:1715-1725.
14. Igarashi K, Kataoka K, Itoh K, Hayashi N, Nishizawa M, Yamamoto M. Regulation of transcription by dimerization of erythroid factor NF-E2 p45 with small Maf proteins. Nature. 1994;367:568-572.
15. Miyoshi H, Ohira M, Shimizu K, et al. Alternative splicing and genomic structure of the AML1 gene involved in acute myeloid leukemia. Nucleic Acids Res. 1995;23:2762-2769.
16. Momeni P, Glockner G, Schmidt O, et al. Mutations in a new gene, encoding a zinc-finger protein, cause tricho-rhino-phalangeal syndrome type I. Nat Genet. 2000;24:71-74.
17. Chang GT, Steenbeek M, Schippers E, et al. Characterization of a zinc-finger protein and its association with apoptosis in prostate cancer cells. J Natl Cancer Inst. 2000;92:1414-1421.
18. McCarty AS, Kleiger G, Eisenberg D, Smale ST. Selective dimerization of a C2H2 zinc finger subfamily. Mol Cell. 2003;11:459-470.
19. Michaud J, Wu F, Osato M, et al. In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis. Blood. 2002;99:1364-1372.
20. Elagib KE, Racke FK, Mogass M, Khetawat R, Delehanty LL, Goldfarb AN. RUNX1 and GATA-1 coexpression and cooperation in megakaryocytic differentiation. Blood. 2003;101:4333-4341.
21. Xu G, Kanezaki R, Toki T, et al. Physical association of the patient-specific GATA1 mutants with RUNX1 in acute megakaryoblastic leukemia accompanying Down syndrome. Leukemia. 2006;20;1002-1008.
22. Osato M, Ito Y. Increased dosage of the RUNX1/AML1 gene: a third mode of RUNX leukemia? Crit Rev Eukaryot Gene Expr. 2005;15:217-228.
23. So CW, Clearly ML. Dimerization: a versatile switch for oncogenesis. Blood. 2004;104:919-922.
24. Chan EM, Comer EM, Brown FC, et al. AML1-FOG2 fusion protein in myelodysplasia. Blood. 2005;105:4523-4526.
25. Choi Y, Elagib KE, Delehanty LL, Goldfarb AN. Erythroid inhibition by the leukemic fusion AML1-ETO is associated with impaired acetylation of the major erythroid transcription factor GATA-1. Cancer Res. 2006;66:2990-2996.